Spectral AI, Inc. Class A (MDAI)

Over the past six months, Spectral AI, Inc.'s stock price experienced a decline of 28.18%. The DeepView System was featured at the 2025 US Burn Conferences in November 2025. Spectral AI announced its 2025 Third Quarter Financial Results on November 11, 2025, reporting an earnings per share of -$0.13, missing the consensus estimate of -$0.08, and revenue for the quarter was $3.79 million, also below analysts' expectations of $5.06 million. In October 2025, Spectral AI raised $7.6 million in additional growth capital. Spectral AI was named to TIME's List of World's Top HealthTech Companies 2025 in September 2025. The company applied for De Novo review with the FDA in June 2025, with a decision anticipated between Q1 and early Q2 2026.

Based on the available information, there is no explicit data detailing the demand seasonality for Spectral AI, Inc.'s products and services. The company's focus on medical diagnostics for wound care suggests that demand may be driven more by medical necessity and incidence rates rather than seasonal fluctuations.

Spectral AI, Inc. is a predictive artificial intelligence company focused on medical diagnostics for accurate treatment decisions in wound care, operating within the Healthcare sector, specifically in the Health Care Equipment and Diagnostic Equipment industry and categorized under Medical Specialties. The company's primary product is the DeepView System, an internally developed multispectral imaging device that utilizes proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue, providing an objective and immediate assessment of a wound's healing potential. The DeepView System is applied in wound care for burns and diabetic foot ulcers, and is being developed for future clinical applications.

Spectral AI, Inc. is headquartered in Dallas, Texas, United States, and maintains an office in Welwyn Garden City, Herts, UK. The company is actively pursuing regulatory clearances and conducting pivotal clinical trial programs for its DeepView System in the UK, US, and Europe.

In the past year, Spectral AI's brand reputation has seen both positive recognition and challenges. A significant positive event was being named to TIME's List of World's Top HealthTech Companies 2025. However, the company's stock underperformed the US Medical Equipment industry and the broader US market over the past year, experiencing a notable decline of 28.18% from January 2025 to January 2026. The company's Q3 2025 earnings missed analyst expectations, which can negatively impact investor sentiment. Analyst ratings for Spectral AI vary, with some sources indicating a "Hold" consensus and others a "Strong Buy" or "Buy" consensus.

Ownership of Spectral AI, Inc. stock is distributed among institutional, individual, and retail investors. Institutional investors hold between approximately 9.61% and 67.08% of the company's stock, with major institutional shareholders including Highlander Partners, L.P., and Vanguard Group Inc. Insiders hold approximately 8.85% to 44.43% of the stock, with John Michael DiMaio being the largest individual shareholder. Retail investors hold a substantial portion, estimated at 45.96% to 81.22% of the stock.